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planned surgery or intervention. Difference of success and access site complication rate
was tested with chi square test. OR and its 95% CI were calculated with multivariate
logistic regression analysis adjusted by patient background.
Results: 16 (19.5%) and 2 (11.1%) patients had access site complications in 18Fr and
14Fr group, respectively. No significant difference was obtained (p  0.52). 73 (89.0%)
and 18 (100%) patients had successful TAVI in 18Fr and 14Fr group, respectively. No
statistical difference was observed in success rate as well (p  0.36). Although 14 Fr
group showed shorter fluoroscopic time, it was not significant (26.4 vs 27.2 min, p 
0.77). There was no difference in contrast amount (133.8 vs 141.4ml, p 0.67). Adjusted
OR of access site complication in 14 Fr compared to 18Fr was 0.20 (95%CI: 0.03-1.59,
p 0.12). OR of successful TAVI was not calculative since no failed case was observed
in 14Fr group.
Conclusions: Compared with standard 18Fr sheath, 14Fr balloon expandable sheath
showed lower complication rate, higher success rate, shorter fluoroscopic time and smaller
amount of contrast use but they did not reach statistical significance. Further investigation
should be needed.
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Background: Pulmonary Hypertension (PH) is considered a significant risk factor in
patients with aortic valve disease for and the prognostic implicationions of PH are unclear
in high-risk patients undergoing Transcatheter Aortic Valve Implantation (TAVI).
Therefore, we sought to assessed the impact of preoperative PH on outcome in patients
undergoing TAVI.
Methods: Between January 2009 and June 2010, a total of 1285 patients undergoing
TAVI were included in this registry (mean age 81.76.1, 41.9% males). Patients were
grouped according to systolic pulmonary artery pressure (PASP): group I, 277 patients,
(21.6%) with PASP30mmHg, group II, 598 patients (46.5%) with PASP 30-50 mmHg
and group III, 410 patients (31.9%) PASP 50mmHg. Patients in group III had a
significantly higher Euroscore (2616mmHG vs. group I 1811mmHg vs. group II
1811mmHg; p0.0001) and were more symptomatic with a higher proportion
presenting in NYHA class IV (28.5% vs. group I 13.6% vs. group II 8.3%; p0.0001).
Results: In all subgroups, the majority of procedures was performed transfemorally with
a high procedural success rate. The rate of TAVI-associated complications was compa-
rable independent of PASP (cerebrovascular accident: group I 3.3% vs. group II 3.9 % vs.
group III 2.0%, p0.25; permanent pacemaker: group I 33.8% vs. group II 38.1 % vs.
group III 35.2%, p0.24). Functional NYHA class and survival at 30 days demonstrated
excellent outcome in all subgroups (30-day survival group I: 91.2% vs. group II 93.0% vs.
group III 91.9%; p0.59). All subgroups experienced a significant improvement of
self-assessed quality-of-life (according to EuroQol5d-visual analogue scale) with the
largest gain in group III (0.1120.35 vs. group I 0.0550.32 vs. group II 0.040.32;
p0.15).
Conclusions: In conclusion, non-surgical patients severe AS have a high prevalence of
PH. However, based on the registry data, early mortality after TAVI is not increased in
patients with PH. This subgroup benefit from the procedure with functional improvement
and improved postoperative quality-of-life.
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Background: Percutaneous transcatheter aortic valve implantation (TAVI) is a proven
therapy for patients at high risk for surgical AV replacement. Although numerous studies
have reported the safety and efficacy of TAVI, integration of this therapy into standard of
care varies widely by country, and country-or region-specific data could support local
adoption and approval. The CoreValve Australia-New Zealand Study (ANZ) is evaluating
the safety and effectiveness of the CoreValve System (Medtronic, Minneapolis, MN) in an
Australia-New Zealand patient population.
Methods: ANZ is a prospective, multicenter, single-arm, study enrolling patients with
severe symptomatic AS from 10 experienced centers. Primary safety endpoints were;
cardiac death (CD) and major adverse cardiovascular/ cerebrovascular events (MACCE;
all-cause death, myocardial infarction [MI], stroke, or reintervention) at 30 days. All
clinical source documentation will be fully monitored. An independent Clinical Events
Committee adjudicated MACCE events and death based on VARC.
Results: Baseline characteristics (n428) include: 45% women, age 83.95.9 y; 76.7%
NYHA Class III/IV, STS 5.94.2, logEuroSCORE 17.611.0, 35.3% atrial fibrillation,
31.3% prior PCI, 25.7%,previous CABG; 20.1% prior MI, and prior balloon valvulo-
plasty in 22.7%. Procedural success was 98.4%.Vascular complications, major 4.0%;
bleeding, life- threatening/disabling 4.7%, major 8.9%. At 30 days, 97.9% of patients
were free from CD, 96.4% from stroke, and 85.8% from MACCE. 79.8% improved 1
NYHA class. AV area significantly improved by 1.20.5 cm2 and mean gradient by
41.716.7 mmHg; 81.6% of patients had  mild AR. At 1 year, 93.5% were free from
CD, 94.7% from stroke and 78.0% from MACCE. NYHA, AR, AV area and mean
gradient improvements persisted at 1 year. PPM rates were evaluated by experience; for
30 implants, the PPM rate was 33.1%; for 30 implants; 19.9%. No valve migrations
have been reported.
Conclusions: Early to midterm outcomes showed mortality and morbidity outcomes
within expectations for percutaneously treated patients with severe symptomatic AS in
this very high-risk subgroup. Longer term follow-up will be presented at the time of the
meeting.
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Background: Transcatheter aortic valve implantation (TAVI) has emerged as a valuable
option to treat patients with symptomatic severe aortic stenosis not being considered for
surgery because of significant comorbidities. Concerns exist about treating patients who
previously underwent mitral valve surgery for possible interference between the percu-
taneous aortic valve and the mitral prosthesis or ring.
Methods: At our Center from May 2008 one hundred sixty-one patients (74 male) with
severe symptomatic aortic stenosis, mean age 819 years, were eligible for TAVI. Nine
patients affected by severe aortic stenosis, previously underwent mitral valve surgery (4
mono-leaflet, 3 bi-leaflet, 1 bioprosthesis, 1 mitral ring); they were judged high risk
surgical candidates, after combined cardiac surgeons and cardiologist evaluation, and
underwent TAVI (Table I).
Results: Seven patients underwent standard femoral retrograde CoreValve implantation,
two patient underwent a direct aortic implantation through a mini-thoracotomy. All
patients experience immediate improvement of the hemodynamic status. No deformation
of the nitinol tubing of the CoreValve neither distortion or malfunction of the mechanical
valve or mitral ring occurred as assessed by echographic and fluoroscopic evaluation. No
major post-operative complications occurred. In all patients echocardiography evidenced
normal valve function during follow-up.
Patient characteristics and results
Nr % or SD
Gender (female) 7 77.7%
Mean Age (years) 73.7 6.6
Left Ventricle Ejection Fraction (%) 34 12
Mean Aoric Gradient (mmHg) 48 14
Mean STS Score Mortality (%) 13.3 10.5
PM Implant 0 –
Stroke 0 –
30-day Mortality 0 –
Conclusions: Our experience confirms the safety and feasibility of CoreValve implan-
tation in patients with mechanical / biological mitral valves or mitral annuloplasty ring.
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Background: So far device sizing before TAVI is recommended by Echo measurements
which are however known to be somehow inaccurate taking into acount the oval shape of
the anulus and device undersizing is a major cause for paravalvular regurgitation. In the
current study we therefore assessed the post implantation expansion pattern and the
functional performance of the Edwards Sapien XT (Edwards Lifesciences, California)
device after TAVI and a MSCT guided sizing approach.
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Methods: Pre- and postprocedural MSCT was performed in 40 patients. TAVI size
selection was done on the basis of anulus cross sectional measurements by MSCT so that
the nominal TAVI device CSA always exceeded the anNulus CSA. In preprocedural data
sets we determined the valve calcium score, the CSA and the ovality index of the aortic
anulus. In postprocedural data sets maximum and minimum diameter and the degree of
circularity at three levels (ventricular end, anulus, aortic end) was determined.
Results: The average expansion ratio of the Edwards Sapien XT device was 95% and the
circularity Index was 97%. In multivariate regression analysis neither calcium score nor
ovality index of the native anulus were associated with under or non circular expansion
of the device. The only parameter predicting underexpansion was the degree of
oversizing. Underexpansion of the device was not associated with increased transaortic
pressure gradients or with the incidence of paravalvular aortic regurgitation. The degree
of oversizing was however positiveley associated with the incidence of new conduction
disturbances. In the entire cohort no aortic regurgitation  mild was observed.
Conclusions: MSCT guided TAVI device sizing is associated with almost complete and
symmetric expansion of the Edwards Sapien XT device and the absence of significant
aortic regurgitation. Calcification or ovality of the native anulus do not influence the
expansion pattern. To rigorous device oversizing however is associated with new
conduction disturbances and device underexpansion.
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Background: New left bundle branch block (LBBB) or need for permanent pacing due
to AV-block are frequent after transcatheter aortic valve implantation (TAVI). This study
evaluated the impact of new conduction defect after TAVI on the evolution of left
ventricular (LV) function during one year follow-up.
Methods: A total of 90 consecutive patients treated with TAVI and 12 months
echocardiographic follow-up were included in the study. In 39 patients a new conduction
defect (new LBBB or need for permanent pacemaker activity) persisted one month after
TAVI. In 51 patients no persistent new conduction defect was observed. 2D echocardi-
ography using parasternal short-axis, apical 4-chamber and 2-chamber views was
performed before TAVI and at 1 year follow-up to determine left ventricular volumes and
ejection fraction based on Simpson’s rule. Speckle-tracking echocardiography was
applied using standard LV short-axis images to assess the effect of new conduction defect
on time-to-peak radial strain of different LV segments as parameter of LV dyssynchrony.
Results: New conduction defect resulted in marked heterogeneity in time-to-peak strain
between the 6 analysed short-axis segments. During one year follow-up after TAVI there
was a significant increase in LVEF in patients without new LBBB (5311% pre to
5910% at follow-up; p0.001), while there was no change in LVEF in patients with
new conduction defect (5211% pre to 5112% at follow-up, p0.740). Change in LV
endsystolic volume was also significantly different between patient groups (1.014.2
vs. 11.215.7 ml, p0.042). New conduction defect was an independent predictor of
reduced LVEF at 12 months follow-up after TAVI.
Conclusions: LVEF improves after TAVI for treatment of severe aortic stenosis in
patients without new conduction defect. In patients with a new conduction defect after
TAVI, there is no improvement in LVEF at follow-up.
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Background: Transthoracic echocardiography (TTE) is the reference technique for
evaluating aortic stenosis (AS), but in certain cases, estimation of the average gradient and
aortic valve area can be difficult. We aimed to assess the feasibility and utility of
measuring simultaneous transaortic pressure using a fractional flow reserve (FFR)
guidewire in doubtful aortic stenosis.
Methods: Between January 2009 and December 2011, 57 patients with symptoms
possibly related to severe AS that was poorly evaluated by echocardiography underwent
right and left heart catheterization for assessment of aortic valve area with the Gorlin &
Gorlin formula. Transaortic pressure was obtained by 2 invasive methods, namely
conventional pullback method from the left ventricle (LV) towards the aorta (PM) with
subsequent computerized superposition of the pressure curves, and (2) simultaneous
method using a FFR wire introduced into the LV (SM).
Results: Reasons for inaccurate assessment by echocardiography were atrial fibrillation
(75%) and/or low LV ejection fraction (38%). Results of evaluation of mean aortic valve
gradient and aortic valve area are summarized in the table below. Agreement between
methods (using the kappa coefficient) for severe aortic stenosis defined by an aortic-valve
area 0.6 cm2/m2 was 0.36 between SM and PM, 0.07 between SM and TTE, and0.12
between PM and TTE. These findings led to a decision to change therapeutic strategy in
8 patients (14%).
Conclusions: Simultaneous measurement of trans-aortic pressure using a FFR guidewire











p vs Pullback 0.0001 — 0.0002




p vs Pullback 0.003 — 0.529
p vs echo 0.074 — —
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Background: Patients with severe aortic stenosis, but who are not good candidates for
surgical aortic valve replacement can be treated with trans-catheter aortic valve implan-
tation (TAVI). This latest technology however comes at a considerable cost. The objective
of the current study is to calculate and analyse these costs.
Methods: Data were retrospectively collected from all patients who underwent a
transaortic valve insertion in the University Hospital Antwerp from December 2007 until
June 2011. Costs of hospitalisation were retrieved on the basis of invoices and patients
characteristics from medical records. Costs were actualized to 2011 using 2011 tariffs and
determinants analysed (Wilcoxon rank sum test and Spearman rho’s correlation).
Results: 89 patients were included. Analyses are performed on 86 patients with complete
cost data. All interventions were done by a single physician using Core Valve ®. Mean
age of the patients was 82 years; 73% of patients are in NYHA 3 and 4. Mean costs
amount to €38,521 (sd €8,587) with median costs only slightly smaller (€37,079). The
costs of the valve (€17,090 per valve) and daily nursing and hotel costs (€ 594 per day)
are most important, amounting to respectively 46% and 26% of total costs. There is weak
evidence of a learning effect: costs decrease somewhat over the years (p0.091).
Pulmonary hypertension (p0.04) and hyperlipidemia (0.0049) have a siginificant
association with costs as well. The distribution of costs is not significantly different for
other background characteristics of the patient. (see table 1)
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